Puberty Initiation in Turner Syndrome
Start low-dose transdermal 17β-estradiol at age 11-12 years (or when FSH is elevated), beginning with 6.25 μg/day via patch, then gradually escalate the dose every 6-12 months over 2-3 years to mimic physiological puberty, adding cyclic progestogen after 2 years of estrogen therapy or when breakthrough bleeding occurs. 1
Initial Assessment and Timing
Check FSH levels around age 11-12 years to confirm hypergonadotropic hypogonadism. If FSH is elevated and there is no spontaneous pubertal development, initiate estrogen replacement immediately at this age 1. Do not delay treatment, as postponing estrogen replacement may be detrimental to bone health and uterine development 2.
Estrogen Regimen: Step-by-Step Protocol
Ages 12-13 Years: Initiation Phase
- First choice: Transdermal 17β-estradiol patch at 6.25 μg/day 1
- Alternative if transdermal unavailable: Oral micronized estradiol 5 μg/kg/day or 0.25 mg/day 1
- Avoid ethinylestradiol and conjugated equine estrogens - these are inferior to 17β-estradiol 1, 2
Ages 12.5-15 Years: Escalation Phase
Increase estradiol dose gradually at 6-12 month intervals over 2-3 years 1:
Transdermal dosing progression:
- 6.25 → 12.5 → 25 → 37.5 → 50 → 75 → 100 μg/day
- Adult maintenance dose: 100-200 μg/day 1
Oral dosing progression (if transdermal not feasible):
- 5 → 7.5 → 10 → 15 μg/kg/day
- Adult maintenance dose: 2-4 mg/day 1
Important caveat: If the patient is receiving concurrent growth hormone therapy and height optimization is a priority, escalate estradiol doses more slowly. For late-diagnosed patients where growth is not a consideration, you may start at higher doses and escalate more rapidly 1.
Ages 14-16 Years: Adding Progestogen
Add cyclic progestogen after at least 2 years of estrogen therapy or when breakthrough bleeding occurs 1:
- Preferred options: Oral micronized progesterone 100-200 mg/day OR dydrogesterone 5-10 mg/day for 12-14 days per month 1
- These are preferred over other progestogens due to less negative effects on lipid metabolism and fewer androgenic effects 1
Why Transdermal is Superior
17β-estradiol via transdermal route is the gold standard because it:
- More closely mimics physiological estrogen secretion 3, 2
- Avoids first-pass hepatic metabolism 3
- Has better effects on lipid profiles and liver enzymes compared to oral preparations 2
- May lead to better long-term bone health outcomes 4
Practical Considerations
If transdermal patches are poorly tolerated or compliance is an issue:
- Switch to oral micronized 17β-estradiol (second choice) 3
- Percutaneous estradiol gel is another effective alternative that has been shown to produce gradual pubertal development 5
- Only use ethinyl estradiol as a last resort when other preparations are unavailable 2
Dose fractionation challenge: The lowest commercially available patches typically deliver 25-50 μg/day, not the recommended starting dose of 6.25 μg/day. Methods like administering 1/8 or 1/4 of a patch have been suggested, but equivalence is not established 1. Consider starting with the lowest available commercial dose if fractionation is impractical.
Monitoring
- Annual clinical review once therapy is established, with particular attention to compliance 1
- No routine laboratory monitoring is required unless prompted by specific symptoms or concerns 1
- Monitor pubertal progression clinically (breast development, uterine growth via ultrasound if needed)
Common Pitfalls to Avoid
- Starting too late: Delaying beyond age 12 years can compromise bone density acquisition and uterine development 4, 2
- Starting with too high a dose: This can compromise final height potential, especially in patients on growth hormone 1
- Using conjugated equine estrogens or ethinylestradiol as first-line: These have inferior metabolic profiles 1, 2
- Adding progestogen too early: Wait at least 2 years to allow adequate breast and uterine development 1